Life Sciences & Healthcare

CSL Moves Up International Biotech Market Capitalisation Rankings Driven By R&D Investment

January 20th, 2020

A report in the Australian Financial Review has highlighted the remarkable performance of CSL over recent years, largely due to the company’s investment in R&D Activity. The report has highlighted: CSL’s share price has increased more than 50% during 2019, which is rare for a company of such size and maturity; If CSL maintains their current trajectory, it may shortly overtake Commonwealth Bank of Australia as the 2nd most valuable stock on the ASX by market capitalisation; CSL is now […]

Read More

Global Veterinary Surgical Instrument Projected Growth due to R&D Incentives

April 8th, 2019

A study involving some of the biggest veterinary surgical instruments manufacturers predicts a growth of approximately 6.5% during the forecast period 2018- 2023.   The growth is as a result of the rise in R&D expenditure, product innovation and demands in pet care on a global scale as the market is increasing going more competitive. Per a geological analysis, North America is expected to be on the forefront of this market followed by Europe. Asia- pacific will be expected to […]

Read More

Australia’s Attractiveness for Clinical Trials

March 6th, 2019

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Read More

Senate Economics Committee Review Into Proposed R&D Tax Incentive Changes

January 31st, 2019

The Senate Economics Legislation Committee conducted a public hearing in Melbourne on 30 January which heard submissions from various stakeholders including: Cochlear Ltd; Brickworks Ltd; CSL; Dulux Group; The AFR has reported that representatives from these groups have consistently argued that continual change to R&D Tax Incentive introduces uncertainty and reduces Australia’s relative attractiveness as an investment location. In fact, R&D spending in Australia has fallen by over $2 billion since 2013-14. The proposed intensity threshold for companies with annual turnover […]

Read More

Email this job

[recaptcha]